Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

Published 56 minutes agoALT

Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

Altimmune, Inc. is drawing attention as it prepares to release its first-quarter 2025 earnings report. The company is expected to announce its financial results on May 8, 2025. This upcoming report has investors eager to see how the company is faring as it continues to advance its clinical trials.

In the fourth quarter of 2024, Altimmune managed to exceed analysts' expectations by reporting a net loss of $23.2 million, or $0.33 per share, compared to the projected loss of $0.34 per share. This quarter saw significant investment in research and development, amounting to $19.8 million, with $13.6 million earmarked specifically for the development of pemvidutide. Reuters highlighted that this compound is of particular interest due to its ongoing trials targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Recent developments in Altimmune's research efforts include the completion of enrollment in the Phase 2b IMPACT trial for pemvidutide, with results expected in the second quarter of 2025. Additionally, the FDA has approved Investigational New Drug (IND) applications for two more indications of pemvidutide, with corresponding Phase 2 trials expected to start by mid-2025. These advancements, coupled with optimistic revisions in earnings per share estimates by analysts at B. Riley, indicate growing investor confidence in Altimmune's direction as it unfolds.

Share this article

Twitter Facebook LinkedIn

Recent Articles

NHTSA Inquires About Tesla's Upcoming Robotaxi Fleet

NHTSA Inquires About Tesla's Upcoming Robotaxi Fleet

11 minutes agoTSLA

The National Highway Traffic Safety Administration (NHTSA) is seeking detailed information from Tesla concerning its planned robotaxi deployment in Austin, Texas, slated for June 2025. The agency's primary concern revolves around the safety of Tesla's Full Self-Driving (FSD) technology, especially in challenging conditions like fog, rain, and dust, as reported by Reuters. Tesla is required to detail the number of vehicles to be deployed, the systems monitoring these vehicles, the sensors in use, and how these meet current industry standards. This move comes on the heels of some troubling incidents related to the company's self-driving system, including a fatal pedestrian accident in Arizona in 2023 and another involving a motorcyclist in Seattle in 2024. The inquiry from NHTSA is the latest in a series of evaluations on Tesla's automated systems. In December 2023, Tesla executed a massive recall of over 2 million vehicles due to concerns over driver attentiveness under its Autopilot system. The effectiveness of that recall is still under assessment by the NHTSA. For now, Tesla has not yet responded to the questions posed by the agency.

Johnson Controls Upgraded by Deutsche Bank Amid Leadership Change

Johnson Controls Upgraded by Deutsche Bank Amid Leadership Change

26 minutes agoJCI

Johnson Controls has seen an upgrade from Deutsche Bank following the announcement of Joakim Weidemanis as its new CEO. Weidemanis, who previously served as Executive Vice President at Danaher Corporation, is set to take over from George R. Oliver on March 12, 2025. His appointment is seen as a potential catalyst for the company's growth, reflecting Deutsche Bank's confidence in his leadership capabilities. Deutsche Bank's move comes as they anticipate Weidemanis will strengthen Johnson Controls' trajectory by focusing on innovation and enhancing operational efficiency. These strategies are expected to align well with the company's current focus on delivering smart, sustainable building solutions, which positions them competitively in the industry. Weidemanis's leadership is expected to have a favorable impact on Johnson Controls' market standing and financial performance, as the company continues to emphasize strategic growth under his direction. The change in leadership underscores an optimistic outlook from analysts who foresee positive developments in the company's future.

Chegg Cuts 22% of Workforce Due to AI Impact

Chegg Cuts 22% of Workforce Due to AI Impact

41 minutes agoCHGG

Chegg, the online education company, has announced it will lay off around 22% of its employees, which amounts to approximately 248 workers. This decision comes as part of a restructuring strategy prompted by the growing influence of AI technologies within the educational technology sector. Reuters highlighted the increasing challenge Chegg faces as students opt for free AI tools like ChatGPT for academic help, thus reducing Chegg's web traffic. The impact of AI doesn't stop there. Google's expansion of its AI Overviews has further kept internet users within its search ecosystem, lessening the need for students to use external educational resources such as Chegg. As a result, Chegg is planning to close its offices in the U.S. and Canada by the end of the year and will scale back on spending related to marketing, product development, and administration. This restructuring is expected to result in charges of $34 million to $38 million over the next two quarters. Despite these immediate costs, Chegg hopes to see significant savings in the near future, estimating reductions between $45 million and $55 million in 2025, increasing to $100 million to $110 million in 2026. However, the company reported a steep 31% drop in subscribers, bringing their total down to 3.2 million, alongside a 30% decrease in revenue, now at $121 million, during the first quarter of 2025. Such figures illustrate the fiscal pressures Chegg faces in adapting to the AI-driven educational landscape.

Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

Altimmune Gears Up for Q1 2025 Earnings Amid Pemvidutide Developments

56 minutes agoALT

Altimmune, Inc. is drawing attention as it prepares to release its first-quarter 2025 earnings report. The company is expected to announce its financial results on May 8, 2025. This upcoming report has investors eager to see how the company is faring as it continues to advance its clinical trials. In the fourth quarter of 2024, Altimmune managed to exceed analysts' expectations by reporting a net loss of $23.2 million, or $0.33 per share, compared to the projected loss of $0.34 per share. This quarter saw significant investment in research and development, amounting to $19.8 million, with $13.6 million earmarked specifically for the development of pemvidutide. Reuters highlighted that this compound is of particular interest due to its ongoing trials targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). Recent developments in Altimmune's research efforts include the completion of enrollment in the Phase 2b IMPACT trial for pemvidutide, with results expected in the second quarter of 2025. Additionally, the FDA has approved Investigational New Drug (IND) applications for two more indications of pemvidutide, with corresponding Phase 2 trials expected to start by mid-2025. These advancements, coupled with optimistic revisions in earnings per share estimates by analysts at B. Riley, indicate growing investor confidence in Altimmune's direction as it unfolds.